down arrow

HCA Healthcare, Inc.

  • Market Cap: Large Cap
  • Industry: Hospital
  • ISIN: US40412C1018
USD
487.66
0.89 (0.18%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

483.39491.56

52 Week

289.98520.00
Valuation
Technical
Day's Volume

CASH

1.63 M

Shareholding (Mar 2025)

FII

17.41%

Held by 483 FIIs

DII

59.05%

Held by 43 DIIs

Promoter

0.00%

How big is HCA Healthcare, Inc.?

22-Jun-2025

As of Jun 18, HCA Healthcare, Inc. has a market capitalization of $89.6 billion, with recent net sales of $71.6 billion and a net profit of $6.7 billion over the last four quarters.

Market Cap: As of Jun 18, HCA Healthcare, Inc. has a market capitalization of 89,601.76 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, HCA Healthcare, Inc. reported net sales of 71,585.00 million and a net profit of 6,680.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -2,499.00 million and total assets of 59,513.00 million.

Read More

What does HCA Healthcare, Inc. do?

22-Jun-2025

HCA Healthcare, Inc. is a large-cap holding company that operates hospitals and related healthcare entities, with recent net sales of $18.32 billion and a net profit of $1.83 billion. Key metrics include a P/E ratio of 14.00 and a market cap of approximately $89.6 billion.

Overview:<BR>HCA Healthcare, Inc. is a holding company that owns and operates hospitals and related healthcare entities within the hospital industry and is categorized as a large-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 18,321 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 1,825 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 89,601.76 Million (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 14.00<BR>- Dividend Yield: 83.78%<BR>- Debt Equity: -12.34<BR>- Return on Equity: -189.83%<BR>- Price to Book: -25.46<BR><BR>Contact Details:<BR>- Address: 1 Park Plz, NASHVILLE TN: 37203-6527<BR>- Tel: 1 615 3449551<BR>- Website: https://hcahealthcare.com/

Read More

Who are in the management team of HCA Healthcare, Inc.?

22-Jun-2025

As of March 2022, the management team of HCA Healthcare, Inc. includes Chairman Thomas Frist, CEO Samuel Hazen, and several independent directors: Meg Crofton, Robert Dennis, Nancy-Ann DeParle, and Charles Holliday. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of HCA Healthcare, Inc. includes the following individuals:<BR><BR>- Mr. Thomas Frist, Chairman of the Board<BR>- Mr. Samuel Hazen, Chief Executive Officer and Director<BR>- Mr. William Frist, Director<BR>- Ms. Meg Crofton, Independent Director<BR>- Mr. Robert Dennis, Independent Director<BR>- Ms. Nancy-Ann DeParle, Independent Director<BR>- Mr. Charles Holliday, Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is HCA Healthcare, Inc. overvalued or undervalued?

20-Sep-2025

As of July 20, 2021, HCA Healthcare, Inc. is considered a risky investment due to its overvaluation indicated by a P/E ratio of 14, a negative Price to Book Value of -26.28, and an EV to EBITDA ratio of 9.56, despite a lower PEG ratio of 1.15 compared to peers and a strong year-to-date stock return of 33.62%.

As of 20 July 2021, the valuation grade for HCA Healthcare, Inc. has moved from attractive to risky, indicating a shift in its investment appeal. The company appears to be overvalued, as evidenced by its P/E ratio of 14, which is higher than the peer average of approximately 14.21, and a significantly negative Price to Book Value of -26.28. Additionally, the EV to EBITDA ratio stands at 9.56, which is also above the industry average, suggesting that the company may not be a favorable investment at its current price.<BR><BR>In terms of peer comparison, HCA Healthcare's PEG ratio of 1.15 is lower than the peer average of 1.48, indicating that it may be undervalued in terms of growth expectations relative to its price. However, the overall financial metrics point to a concerning valuation. Notably, HCA's stock has returned 33.62% year-to-date, significantly outperforming the S&P 500's 12.22% return, but this strong performance may not be sustainable given the current valuation risks.

Read More

Is HCA Healthcare, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, HCA Healthcare, Inc. shows a bullish technical trend with strong MACD and moving averages, having outperformed the S&P 500 year-to-date but underperformed over the past year.

As of 4 September 2025, the technical trend for HCA Healthcare, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, while the moving averages indicate a bullish stance on the daily chart. The Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. However, the KST and OBV indicators are mildly bearish on the weekly chart, with the OBV being bullish on the monthly. Dow Theory indicates a bullish trend on the monthly but no trend on the weekly.<BR><BR>In terms of performance, HCA Healthcare has outperformed the S&P 500 year-to-date with a return of 33.62% compared to the S&P 500's 12.22%, but it has underperformed over the past year with a return of 0.29% versus 17.14% for the index. Overall, the current technical stance is bullish, supported by strong MACD and moving average indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - Negative Book Value

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 48.83%, its profits have risen by 5.2% ; the PEG ratio of the company is 1.2
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Hospital

stock-summary
Market cap

USD 97,833 Million (Large Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

76.73%

stock-summary
Debt Equity

-9.89

stock-summary
Return on Equity

-156.67%

stock-summary
Price to Book

-22.27

Revenue and Profits:
Net Sales:
18,605 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,891 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.48%
0%
18.48%
6 Months
27.77%
0%
27.77%
1 Year
50.47%
0%
50.47%
2 Years
89.65%
0%
89.65%
3 Years
104.02%
0%
104.02%
4 Years
112.0%
0%
112.0%
5 Years
209.27%
0%
209.27%

HCA Healthcare, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
HCA Healthcare Hits New 52-Week High of $443.28, Showcasing Strong Performance

HCA Healthcare Hits New 52-Week High of $443.28, Showcasing Strong Performance

HCA Healthcare, Inc. achieved a new 52-week high of USD 443.28 on October 22, 2025, reflecting strong performance in the hospital sector with a 29.28% increase over the past year. The company has a market capitalization of USD 97,833 million and notable financial metrics, including a P/E ratio of 14.00.

Read More
HCA Healthcare Hits New 52-Week High of $439.01, Surges 28.22%

HCA Healthcare Hits New 52-Week High of $439.01, Surges 28.22%

HCA Healthcare, Inc. achieved a new 52-week high of USD 439.01 on October 7, 2025, reflecting strong performance in the hospital industry. The company has seen a 28.22% growth over the past year, significantly outperforming the S&P 500, and offers a notable dividend yield.

Read More
HCA Healthcare, Inc. Hits New 52-Week High of $435.03

HCA Healthcare, Inc. Hits New 52-Week High of $435.03

HCA Healthcare, Inc. reached a new 52-week high of USD 435.03 on October 6, 2025, reflecting its strong performance in the hospital sector. The company has seen a notable increase over the past year and offers a substantial dividend yield, indicating its commitment to shareholder value.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
7.71%
EBIT Growth (5y)
11.85%
EBIT to Interest (avg)
5.33
Debt to EBITDA (avg)
2.95
Net Debt to Equity (avg)
-12.34
Sales to Capital Employed (avg)
1.73
Tax Ratio
22.35%
Dividend Payout Ratio
12.00%
Pledged Shares
0
Institutional Holding
66.63%
ROCE (avg)
27.03%
ROE (avg)
2,133.20%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
-26.28
EV to EBIT
12.53
EV to EBITDA
9.56
EV to Capital Employed
3.41
EV to Sales
1.90
PEG Ratio
1.15
Dividend Yield
79.42%
ROCE (Latest)
27.18%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 180 Schemes (23.53%)

Foreign Institutions

Held by 483 Foreign Institutions (17.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 1.55% vs 0.20% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.62% vs 8.24% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18,605.00",
          "val2": "18,321.00",
          "chgp": "1.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,830.00",
          "val2": "3,715.00",
          "chgp": "3.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "568.00",
          "val2": "547.00",
          "chgp": "3.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,891.00",
          "val2": "1,825.00",
          "chgp": "3.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "159.50%",
          "val2": "155.80%",
          "chgp": "0.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.67% vs 7.86% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.29% vs -10.87% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "70,603.00",
          "val2": "64,968.00",
          "chgp": "8.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "13,859.00",
          "val2": "12,704.00",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2,061.00",
          "val2": "1,938.00",
          "chgp": "6.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,657.00",
          "val2": "6,091.00",
          "chgp": "9.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "149.40%",
          "val2": "148.20%",
          "chgp": "0.12%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
18,605.00
18,321.00
1.55%
Operating Profit (PBDIT) excl Other Income
3,830.00
3,715.00
3.10%
Interest
568.00
547.00
3.84%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,891.00
1,825.00
3.62%
Operating Profit Margin (Excl OI)
159.50%
155.80%
0.37%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 1.55% vs 0.20% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 3.62% vs 8.24% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
70,603.00
64,968.00
8.67%
Operating Profit (PBDIT) excl Other Income
13,859.00
12,704.00
9.09%
Interest
2,061.00
1,938.00
6.35%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6,657.00
6,091.00
9.29%
Operating Profit Margin (Excl OI)
149.40%
148.20%
0.12%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.67% vs 7.86% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 9.29% vs -10.87% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About HCA Healthcare, Inc. stock-summary
stock-summary
HCA Healthcare, Inc.
Hospital
HCA Healthcare, Inc., formerly HCA Holdings, Inc., is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. As of December 31, 2016, the American Group included 80 hospitals, which were located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. As of December 31, 2016, the Company operated six hospitals in England. The Company owns, manages or operates hospitals, freestanding surgery centers and freestanding emergency care facilities, walk-in clinics, diagnostic and imaging centers, among others.
Company Coordinates stock-summary
Company Details
1 Park Plz , NASHVILLE TN : 37203-6527
stock-summary
Tel: 1 615 3449551
stock-summary
https://hcahealthcare.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."